Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 318Squamous Cell Carcinoma of Head and Neck 169Head and Neck Neoplasms 151Carcinoma, Non-Small-Cell Lung 97Colonic Neoplasms 90Rectal Neoplasms 82Neoplasm Metastasis 72Neoplasms 60Pancreatic Neoplasms 40Carcinoma, Squamous Cell 40Lung Neoplasms 35Esophageal Neoplasms 25Breast Neoplasms 22Stomach Neoplasms 20Recurrence 20Carcinoma 18Laryngeal Neoplasms 17Tongue Neoplasms 16Mouth Neoplasms 16Oropharyngeal Neoplasms 14Esophageal Squamous Cell Carcinoma 14Salivary Gland Neoplasms 12Adenocarcinoma Of Esophagus 12Hypopharyngeal Neoplasms 11Colorectal Cancer Metastatic 11Laryngeal Diseases 10Adenocarcinoma of Lung 10Uterine Cervical Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 9Ovarian Neoplasms 9

Interventions

Cyclophosphamide 23blinatumomab 18Cytarabine 16fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Blood Specimen Collection 8Methotrexate 7Lenalidomide 7Dexamethasone 7Daunorubicin 7Mercaptopurine 6Vincristine 5daratumumab 4Whole-Body Irradiation 4Melphalan 4Idarubicin 4Etoposide 4Drug Therapy 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Neoadjuvant Therapy 3Maintenance 3Liquid Biopsy 3Immunotherapy, Adoptive 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Cetuximab × Clear all
NCT06358430 2026-05-20

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

M.D. Anderson Cancer Center

Phase 1 Recruiting
42 enrolled
Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡